TACTILE SYSTEMS TECHNOLOGY I (TCMD) Stock Fundamental Analysis
NASDAQ:TCMD - Nasdaq - US87357P1003 - Common Stock - Currency: USD
Taking everything into account, TCMD scores 6 out of 10 in our fundamental rating. TCMD was compared to 188 industry peers in the Health Care Equipment & Supplies industry. While TCMD has a great health rating, its profitability is only average at the moment. TCMD may be a bit undervalued, certainly considering the very reasonable score on growth This makes TCMD very considerable for value investing!
1. Profitability
1.1 Basic Checks
In the past year TCMD was profitable.
TCMD had a positive operating cash flow in the past year.
In multiple years TCMD reported negative net income over the last 5 years.
Each year in the past 5 years TCMD had a positive operating cash flow.
1.2 Ratios
TCMD has a Return On Assets of 5.78%. This is amongst the best in the industry. TCMD outperforms 85.64% of its industry peers.
TCMD has a Return On Equity of 7.88%. This is amongst the best in the industry. TCMD outperforms 82.98% of its industry peers.
TCMD's Return On Invested Capital of 6.08% is amongst the best of the industry. TCMD outperforms 80.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.78% | ||
| ROE | 7.88% | ||
| ROIC | 6.08% |
ROA(3y)2.94%
ROA(5y)0.73%
ROE(3y)2.6%
ROE(5y)-0.37%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TCMD has a better Profit Margin (5.52%) than 78.72% of its industry peers.
TCMD's Profit Margin has been stable in the last couple of years.
TCMD has a better Operating Margin (7.03%) than 76.06% of its industry peers.
TCMD's Operating Margin has improved in the last couple of years.
TCMD has a Gross Margin of 50.78%. This is comparable to the rest of the industry: TCMD outperforms 44.68% of its industry peers.
TCMD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.03% | ||
| PM (TTM) | 5.52% | ||
| GM | 50.78% |
OM growth 3YN/A
OM growth 5Y6.44%
PM growth 3YN/A
PM growth 5Y-0.06%
GM growth 3Y3.35%
GM growth 5Y-0.43%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TCMD is destroying value.
TCMD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TCMD has more shares outstanding
The debt/assets ratio for TCMD has been reduced compared to a year ago.
2.2 Solvency
TCMD has an Altman-Z score of 3.83. This indicates that TCMD is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.83, TCMD is doing good in the industry, outperforming 74.47% of the companies in the same industry.
The Debt to FCF ratio of TCMD is 0.67, which is an excellent value as it means it would take TCMD, only 0.67 years of fcf income to pay off all of its debts.
TCMD has a Debt to FCF ratio of 0.67. This is amongst the best in the industry. TCMD outperforms 93.09% of its industry peers.
TCMD has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.11, TCMD is in line with its industry, outperforming 58.51% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 0.67 | ||
| Altman-Z | 3.83 |
ROIC/WACC0.7
WACC8.67%
2.3 Liquidity
A Current Ratio of 4.52 indicates that TCMD has no problem at all paying its short term obligations.
TCMD has a better Current ratio (4.52) than 70.74% of its industry peers.
A Quick Ratio of 3.99 indicates that TCMD has no problem at all paying its short term obligations.
TCMD's Quick ratio of 3.99 is fine compared to the rest of the industry. TCMD outperforms 72.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.52 | ||
| Quick Ratio | 3.99 |
3. Growth
3.1 Past
TCMD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.45%.
TCMD shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 4.86% yearly.
TCMD shows a small growth in Revenue. In the last year, the Revenue has grown by 5.96%.
Measured over the past years, TCMD shows a quite strong growth in Revenue. The Revenue has been growing by 9.11% on average per year.
EPS 1Y (TTM)-45.45%
EPS 3YN/A
EPS 5Y4.86%
EPS Q2Q%-62.5%
Revenue 1Y (TTM)5.96%
Revenue growth 3Y12.08%
Revenue growth 5Y9.11%
Sales Q2Q%0.29%
3.2 Future
The Earnings Per Share is expected to grow by 29.16% on average over the next years. This is a very strong growth
Based on estimates for the next years, TCMD will show a quite strong growth in Revenue. The Revenue will grow by 8.67% on average per year.
EPS Next Y-19.84%
EPS Next 2Y10.5%
EPS Next 3Y29.16%
EPS Next 5YN/A
Revenue Next Year5.91%
Revenue Next 2Y7.21%
Revenue Next 3Y8.67%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 14.97 indicates a correct valuation of TCMD.
Compared to the rest of the industry, the Price/Earnings ratio of TCMD indicates a rather cheap valuation: TCMD is cheaper than 85.11% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of TCMD to the average of the S&P500 Index (26.25), we can say TCMD is valued slightly cheaper.
Based on the Price/Forward Earnings ratio of 11.40, the valuation of TCMD can be described as reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TCMD indicates a rather cheap valuation: TCMD is cheaper than 88.30% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of TCMD to the average of the S&P500 Index (22.15), we can say TCMD is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.97 | ||
| Fwd PE | 11.4 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, TCMD is valued cheaply inside the industry as 98.40% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of TCMD indicates a rather cheap valuation: TCMD is cheaper than 98.94% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.09 | ||
| EV/EBITDA | 5.16 |
4.3 Compensation for Growth
TCMD has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as TCMD's earnings are expected to grow with 29.16% in the coming years.
PEG (NY)N/A
PEG (5Y)3.08
EPS Next 2Y10.5%
EPS Next 3Y29.16%
5. Dividend
5.1 Amount
TCMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
9.88
-0.02 (-0.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.76%
Inst Owner Change16.23%
Ins Owners1.72%
Ins Owner Change9.34%
Market Cap229.71M
Analysts78.18
Price Target16.32 (65.18%)
Short Float %9.37%
Short Ratio7.86
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.55%
Min EPS beat(2)-82.07%
Max EPS beat(2)24.97%
EPS beat(4)3
Avg EPS beat(4)3.04%
Min EPS beat(4)-82.07%
Max EPS beat(4)53.45%
EPS beat(8)7
Avg EPS beat(8)426.02%
EPS beat(12)9
Avg EPS beat(12)286.31%
EPS beat(16)10
Avg EPS beat(16)190.43%
Revenue beat(2)0
Avg Revenue beat(2)-3.42%
Min Revenue beat(2)-5.08%
Max Revenue beat(2)-1.76%
Revenue beat(4)0
Avg Revenue beat(4)-3.49%
Min Revenue beat(4)-5.72%
Max Revenue beat(4)-1.4%
Revenue beat(8)2
Avg Revenue beat(8)-1.77%
Revenue beat(12)6
Avg Revenue beat(12)0.41%
Revenue beat(16)9
Avg Revenue beat(16)0.23%
PT rev (1m)-18.64%
PT rev (3m)-23.81%
EPS NQ rev (1m)-30.32%
EPS NQ rev (3m)-48.13%
EPS NY rev (1m)-13.49%
EPS NY rev (3m)-31.67%
Revenue NQ rev (1m)-6.03%
Revenue NQ rev (3m)-7.3%
Revenue NY rev (1m)-2.45%
Revenue NY rev (3m)-3.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.97 | ||
| Fwd PE | 11.4 | ||
| P/S | 0.78 | ||
| P/FCF | 6.09 | ||
| P/OCF | 5.72 | ||
| P/B | 1.12 | ||
| P/tB | 1.73 | ||
| EV/EBITDA | 5.16 |
EPS(TTM)0.66
EY6.68%
EPS(NY)0.87
Fwd EY8.78%
FCF(TTM)1.62
FCFY16.43%
OCF(TTM)1.73
OCFY17.48%
SpS12.61
BVpS8.84
TBVpS5.71
PEG (NY)N/A
PEG (5Y)3.08
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.78% | ||
| ROE | 7.88% | ||
| ROCE | 8.41% | ||
| ROIC | 6.08% | ||
| ROICexc | 10.16% | ||
| ROICexgc | 20.26% | ||
| OM | 7.03% | ||
| PM (TTM) | 5.52% | ||
| GM | 50.78% | ||
| FCFM | 12.87% |
ROA(3y)2.94%
ROA(5y)0.73%
ROE(3y)2.6%
ROE(5y)-0.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y15.26%
ROICexc growth 3YN/A
ROICexc growth 5Y1.86%
OM growth 3YN/A
OM growth 5Y6.44%
PM growth 3YN/A
PM growth 5Y-0.06%
GM growth 3Y3.35%
GM growth 5Y-0.43%
F-Score8
Asset Turnover1.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 0.67 | ||
| Debt/EBITDA | 0.82 | ||
| Cap/Depr | 35.07% | ||
| Cap/Sales | 0.82% | ||
| Interest Coverage | 10.47 | ||
| Cash Conversion | 146.06% | ||
| Profit Quality | 233% | ||
| Current Ratio | 4.52 | ||
| Quick Ratio | 3.99 | ||
| Altman-Z | 3.83 |
F-Score8
WACC8.67%
ROIC/WACC0.7
Cap/Depr(3y)35.17%
Cap/Depr(5y)50.34%
Cap/Sales(3y)0.85%
Cap/Sales(5y)0.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-45.45%
EPS 3YN/A
EPS 5Y4.86%
EPS Q2Q%-62.5%
EPS Next Y-19.84%
EPS Next 2Y10.5%
EPS Next 3Y29.16%
EPS Next 5YN/A
Revenue 1Y (TTM)5.96%
Revenue growth 3Y12.08%
Revenue growth 5Y9.11%
Sales Q2Q%0.29%
Revenue Next Year5.91%
Revenue Next 2Y7.21%
Revenue Next 3Y8.67%
Revenue Next 5YN/A
EBIT growth 1Y9.09%
EBIT growth 3YN/A
EBIT growth 5Y16.13%
EBIT Next Year54.41%
EBIT Next 3Y44.27%
EBIT Next 5YN/A
FCF growth 1Y540.65%
FCF growth 3Y420.83%
FCF growth 5YN/A
OCF growth 1Y406.92%
OCF growth 3Y149.11%
OCF growth 5Y74.54%